A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

An Open-Label, Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, A CD19 Targeted 4-1BB Ligand) in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin's Lymphoma (r/r NHL). Englumafusp alfa will be administered by intravenous (IV) infusion in combination with obinutuzumab and in combination with glofitamab. A fixed dose of obinutuzumab (Gpt; pre-treatment) will be administered up to seven days prior to the first administration of englumafusp alfa and seven days prior to the first administration of glofitamab. This entry-into-human study is divided into a dose-escalation stage (Part I and Part II) and a dose expansion stage (Part III).

Study Overview

• Status: Active, not recruiting
• Conditions: Lymphoma, Non-Hodgkin
• Intervention / Treatment: Drug: Tocilizumab; Drug: Englumafusp alfa; Drug: Obinutuzumab; Drug: Glofitamab

• Study Type: Interventional
• Enrollment (Estimated): 498
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Australia
  • Victoria
    • Melbourne, Victoria, Australia, 3004
      • The Alfred Hospital
    • Melbourne, Victoria, Australia, 3000
      • Peter MacCallum Cancer Centre
• Belgium
  • Ghent, Belgium, 9000
    • UZ Gent
• Canada
  • Nova Scotia
    • Halifax, Nova Scotia, Canada, B3H 2Y9
      • Queen Elizabeth Ii Health Sciences Centre
  • Quebec
    • Montreal, Quebec, Canada, H3T 1E2
      • Jewish General Hospital
• China
  • Beijing, China, 100142
    • Beijing Cancer Hospital
  • Jinan, China, 250117
    • Shandong Cancer Hospital
  • Shanghai, China, 201315
    • Fudan University Shanghai Cancer Center
  • Xiamen, China, 361003
    • The First Affiliated Hospital of Xiamen University
• Denmark
  • Aarhus N, Denmark, 8200
    • Aarhus Universitetshospital Skejby
  • København Ø, Denmark, 2100
    • Rigshospitalet
  • Odense C, Denmark, 5000
    • Odense Universitetshospital
• France
  • Lille, France, 59037
    • CHRU de Lille
  • Montpellier, France, 34295
    • CHU Montpellier - Saint Eloi
  • Pierre-Bénite, France, 69495
    • Centre Hospitalier Lyon Sud
  • Rennes, France, 35033
    • CHU DE RENNES - CHU Pontchaillou
• Italy
  • Campania
    • Naples, Campania, Italy, 80131
      • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
  • Lombardy
    • Bergamo, Lombardy, Italy, 24127
      • ASST Papa Giovanni XXIII
    • Milan, Lombardy, Italy, 20141
      • Irccs Istituto Europeo di Oncologia (IEO)
    • Rozzano, Lombardy, Italy, 20089
      • Istituto Clinico Humanitas
• New Zealand
  • Auckland, New Zealand, 1023
    • Auckland City Hospital, Cancer and Blood Research
  • Hamilton, New Zealand, 3204
    • Waikato Hospital - Cancer and Blood Research Trials Unit
• South Korea
  • Busan, South Korea, 49241
    • Pusan National University Hospital
  • Seoul, South Korea, 03080
    • Seoul National University Hospital
  • Seoul, South Korea, 05505
    • Asan Medical Center
  • Seoul, South Korea, 06351
    • Samsung Medical Center
• Spain
  • Barcelona, Spain, 08035
    • Hospital Universitari Vall d'Hebron
  • Madrid, Spain, 28041
    • Hospital Univ. 12 de Octubre
  • Málaga, Spain, 29010
    • Hospital Clinico Universitario Virgen de La Victoria
• United Kingdom
  • Leicester, United Kingdom, LE1 5WW
    • The HOPE Clinical Trials Unit
  • London, United Kingdom, W1T 7HA
    • University College London Hospitals Nhs Foundation Trust
• United States
  • California
    • Pasadena, California, United States, 91105
      • City of Hope Medical Center
    • San Francisco, California, United States, 94158
      • University of California San Francisco
  • Missouri
    • St Louis, Missouri, United States, 63110
      • Washington University School of Medicine
  • Texas
    • Houston, Texas, United States, 77030-4009
      • The University of Texas MD Anderson Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• History or status of a histologically-confirmed hematological malignancy that is expected to express CD19 and CD20; relapse after or failure to respond to at least one prior treatment regimen; no available treatment options that are expected to prolong survival (Part I and II); relapsed after or failed to respond to only one prior systemic treatment regimen (Part III)
• Must have at least one measurable target lesion (>/= 1.5 cm) in its largest dimension by computed tomography scan
• Able and willing to provide a fresh biopsy from a safely accessible site, per Investigator's determination, providing the participant has more than one measurable target lesion
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, or </= 2 for some participants in Part III
• Life expectancy of >/= 12 weeks
• Adverse events from prior anti-cancer therapy must have resolved to Grade </= 1
• Adequate liver, hematological, and renal function
• Negative test results for acute or chronic hepatitis B virus infection
• Negative test results for hepatitis C virus and HIV
• The contraception and abstinence requirements are intended to prevent exposure of an embryo to the study treatment. The reliability of sexual abstinence for male and/or female enrollment eligibility needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of preventing drug exposure
• Female participants: A female participant is eligible to participate if she is not pregnant and not breastfeeding, and if at least one of the following applies: women of non-childbearing potential (WONCBP); women of child bearing potential (WOCBP) who agree to remain abstinent or use two highly effective contraceptive methods with a failure rate of <1% per year during the treatment period and for at least 18 months after obinutuzumab or 3.5 months after the last dose of englumafusp alfa, 2 months after last dose of glofitamab, or 3 months after the last dose of tocilizumab, whichever is longer. Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal occlusion/ ligation, male sexual partner who is sterilized, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices and copper intrauterine devices. Hormonal contraceptive methods must be supplemented by a barrier method; have a negative pregnancy test (blood) within the 7 days prior to the first study treatment administration
• Male participants: During the treatment period and for at least 3 months after obinutuzumab, or 3.5 months after the last dose of englumafusp alfa, 2 months after the last dose of glofitamab, or 2 months after the last dose of tocilizumab whichever is longer, agreement to: Remain abstinent or use contraceptive measures such as a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year, with a partner who is a women of childbearing potential. With pregnant female partner, remain abstinent or use contraceptive measures such as a condom to avoid exposing the embryo; refrain from donating sperm during this same period

Exclusion Criteria:

• Circulating lymphoma cells, defined by out of range (high) absolute lymphocyte count (ALC) or the presence of abnormal cells in the peripheral blood signifying circulating lymphoma cells (for some participants in Part III, ALC only)
• Participants with acute bacterial, viral, or fungal infection at baseline, confirmed by a positive blood culture within 72 hours prior to obinutuzumab infusion or by clinical judgment in the absence of a positive blood culture
• Participants with known active infection, or reactivation of a latent infection, whether bacterial, viral fungal, mycobacterial, or other pathogens (excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics
• Pregnant or breast-feeding or intending to become pregnant during the study
• Prior treatment with systemic immunotherapeutic agents, including, but not limited to, radio-immunoconjugates, antibody-drug conjugates, immune/cytokines or monoclonal antibodies within 4 weeks or five half-lives of the drug, whichever is shorter, before obinutuzumab infusion
• History of treatment-emergent immune-related AEs associated with prior immunotherapeutic agents and auto-immune disease
• Treatment with standard radiotherapy, any chemotherapeutic agent, or treatment with any other investigational or approved anti-cancer agent within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to obinutuzumab infusion
• Prior solid organ transplantation
• Prior allogeneic stem cell transplant
• Autologous stem cell transplant within 100 days prior to obinutuzumab infusion
• History of severe allergic or anaphylactic reactions to monoclonal antibody therapy and confirmed progressive multifocal leukoencephalopathy
• Current or past history of central nervous system (CNS) lymphoma and CNS disease
• Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including diabetes mellitus, history of relevant pulmonary disorders and known autoimmune diseases
• Major surgery or significant traumatic injury < 28 days prior to the Gpt infusion or anticipation of the need for major surgery during study treatment
• Participants with another invasive malignancy in the last 2 years
• Significant cardiovascular disease
• Administration of a live, attenuated vaccine within 4 weeks before Gpt infusion or anticipation that such a live attenuated vaccine will be required during the study
• Received systemic immunosuppressive medications (including but not limited to cyclohosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within two weeks prior to Gpt, with the exception of corticosteroid treatment <=25 mg/day of prednisone or equivalent, however there must be documentation that the participant was on a stable dose of at least a 2-week duration prior to Gpt infusion. Inhaled and topical steroids are permitted

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part I; Combination Dose-Escalation: Mixed r/r NHL participants will receive a fixed dose of obinutuzumab up to seven days prior to first administration of englumafusp alfa. Englumafusp alfa will be administered by intravenous (IV) infusion in combination with obinutuzumab in a three-weekly schedule (Q3W).	Drug: Tocilizumab; Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).; Other Names: Actemra, RoActemra; Drug: Englumafusp alfa; Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).; Other Names: A CD19 Targeted 4-1BB Ligand; RO7227166; Drug: Obinutuzumab; A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa, then in combination with obinutuzumab Q3W (Part I). A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa or between Day -3 and -7 (Part II and Part III).; Other Names: Gpt, RO5072759, Gazyva, Gazyvaro
Experimental: Part II; Combination Dose-Escalation: Mixed r/r participants and participants with mixed r/r mantle cell lymphoma (MCL) and Richters transformation will receive a fixed dose of obinutuzumab seven days prior to first administration of englumafusp alfa. Englumafusp alfa will be administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).	Drug: Tocilizumab; Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).; Other Names: Actemra, RoActemra; Drug: Englumafusp alfa; Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).; Other Names: A CD19 Targeted 4-1BB Ligand; RO7227166; Drug: Obinutuzumab; A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa, then in combination with obinutuzumab Q3W (Part I). A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa or between Day -3 and -7 (Part II and Part III).; Other Names: Gpt, RO5072759, Gazyva, Gazyvaro; Drug: Glofitamab; A fixed dose of glofitamab will be administered Q3W in combination with englumafusp alfa in Part II and Part III; Other Names: CD20-TCB, RO7082859
Experimental: Part III; Dose-Expansion Stage: Participants with r/r diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), high-grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL), and DLBCL arising from FL (transformed FL) will receive englumafusp alfa administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).	Drug: Tocilizumab; Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).; Other Names: Actemra, RoActemra; Drug: Englumafusp alfa; Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).; Other Names: A CD19 Targeted 4-1BB Ligand; RO7227166; Drug: Obinutuzumab; A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa, then in combination with obinutuzumab Q3W (Part I). A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa or between Day -3 and -7 (Part II and Part III).; Other Names: Gpt, RO5072759, Gazyva, Gazyvaro; Drug: Glofitamab; A fixed dose of glofitamab will be administered Q3W in combination with englumafusp alfa in Part II and Part III; Other Names: CD20-TCB, RO7082859

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Nature and frequency of dose-limiting toxicities (DLTs)		28 days in Part I and Part II
Duration of Response (DOR)		After end of Study approximately every 3 months until death, loss to follow-up or study termination
Progression-free Survival (PFS)		After end of Study approximately every 3 months until death, loss to follow-up or study termination
Overall Survival (OS)		After end of Study approximately every 3 months until death, loss to follow-up or study termination
Proportion of Participants with Adverse Event (AE)	Incidence, nature, and severity of AEs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0	Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
Overall Response Rate (ORR)		Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
Disease Control Rate (DCR)		Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
Complete Response (CR)		Part III: Up to 9 months or up to 18 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
DOR		After end of Study approximately every 3 months until death, loss to follow-up or study termination
PFS		After end of Study approximately every 3 months until death, loss to follow-up or study termination
OS		After end of Study approximately every 3 months until death, loss to follow-up or study termination
Proportion of Participants with Adverse Event (AE)	Incidence, nature, and severity of AEs graded according to the NCI CTCAE v5.0	After end of Study approximately every 3 months until death, loss to follow-up or study termination
Time to First Complete Response (TFCR)		Up to 18 months
Time to First Overall Response (TFOR)		Up to 18 months
Total exposure (area under the concentration time curve [AUC]) of englumafusp alfa in combination with obinutuzumab and glofitamab		Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
Maximum serum concentration (peak concentration, Cmax) of englumafusp alfa in combination with obinutuzumab and glofitamab		Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
Minimum serum concentration (trough concentration, Cmin) of englumafusp alfa in combination with obinutuzumab and glofitamab		Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
Clearance (CL) of englumafusp alfa in combination with obinutuzumab and glofitamab		Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
Volume of distribution of steady state (Vss) and half-life (t1/2) of englumafusp alfa in combination with obinutuzumab and glofitamab		Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
ORR		Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
DCR		Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
Total exposure (area under the concentration time curve [AUC]) of englumafusp alfa in combination with glofitamab		Part III: Up to 9 months or up to 18 months
Maximum serum concentration (peak concentration, Cmax) of englumafusp alfa in combination with glofitamab		Part III: Up to 9 months or up to 18 months
Minimum serum concentration (trough concentration, Cmin) of englumafusp alfa in combination with glofitamab		Part III: Up to 9 months or up to 18 months
Clearance (CL) of englumafusp alfa in combination with glofitamab		Part III: Up to 9 months or up to 18 months
Volume of distribution of steady state (Vss) and half-life (t1/2) of englumafusp alfa in combination with glofitamab Part I/II/III		Part III: Up to 9 months or up to 18 months
T-cell and Natural killer (NK)-cell status in blood, using markers of T and NK-cell lineage, function and activation including, but not limited to, CD3, CD8, 41BB, and Ki67 expression		Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
B-cell reduction in blood and tumor tissue		Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
Change from Baseline in englumafusp alfa Anti-Drug Antibody (ADA) Titer		Part 1: Up to 24 months; Part ll/lll: Up to 18 months
Duration of Complete Response (DOCR)		Part III: Up to 9 months or up to 18 months
Change from Baseline in Physical Function, Role Function, and Health-Related Quality of Life (HRQoL) Based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)		Part III: Up to 9 months or up to 18 months
Change from Baseline in Physical Function, Role Function, and HRQoL According to the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Lymphoma Scale		Part III: Up to 9 months or up to 18 months

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche
• Investigators: Study Director: Clinical Trials, Hoffmann-La Roche

Study record dates

Study Major Dates

• Study Start (Actual): August 13, 2019
• Primary Completion (Estimated): March 31, 2027
• Study Completion (Estimated): March 31, 2027

Study Registration Dates

• First Submitted: August 9, 2019
• First Submitted That Met QC Criteria: September 3, 2019
• First Posted (Actual): September 4, 2019

Study Record Updates

• Last Update Posted (Actual): May 29, 2026
• Last Update Submitted That Met QC Criteria: May 28, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Immune System Diseases; Neoplasms by Histologic Type; Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Lymphoma; Hemic and Lymphatic Diseases; Lymphoma, Non-Hodgkin; Enzymes; Enzymes and Coenzymes; Transaminases; Nitrogenous Group Transferases; Transferases; tocilizumab; obinutuzumab; Alanine Transaminase; glofitamab
• Other Study ID Numbers: BP41072; 2019-000416-28 (EudraCT Number); 2022-502616-37-00 (Registry Identifier: EU CT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No